Dr. Bruce A. Cree, MD

Dr. Cree practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Cree's NPI, 1477599454, was assigned on June 20, 2006. Dr. Cree graduated from UCSF School of Medicine in 1997. Dr. Cree holds California license A74576.

Dr. Cree's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Cree's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Cree is also affiliated with Memorial Medical Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Cree to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cree practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Cree's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Cree is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Cree is licensed in California.

Dmand AI lists fibromyalgia and chronic pain, multiple sclerosis and neck pain and spine problems among the conditions Dr. Cree treats.

CMS data shows 293 Medicare services from Dr. Cree across 4 procedure codes in 2024, for 109 Medicare patients. Medicare paid $18,328 for them. Every service was in an office.

CMS counts 109 Medicare patients who saw Dr. Cree in 2024. The largest group is 65 to 74, with 54 patients. 66% of them have high cholesterol, and 54% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Cree's median patient age at 61, with 70% women.

In 2024, Dr. Cree wrote 680 Medicare Part D claims for 90 patients. 80% of them were for generic drugs. CMS names the drug for 481 of them, across 18 drugs with 11 or more claims each, at $1,200,341 in total drug cost. In 2023, CMS named 389 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Cree for performance year 2024, reported as part of a group. Dr. Cree accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cree as offering telehealth.

Dmand AI links 218 papers to Dr. Cree, published from 2003 to 2025. 2020 was the busiest year, with 20. The most frequent topics are Multiple Sclerosis, Magnetic Resonance Imaging and Multiple Sclerosis, Relapsing-Remitting. Dr. Cree has published most often in Ann Neurol. Dr. Cree's most frequent co-authors are Jeffrey Marc Gelfand, MD, Ari J. Green, MD and Stephen L. Hauser, MD.

Dmand AI links Dr. Cree to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive and Myelitis. University of California, San Francisco sponsors the most, 2. Open Payments lists research payments to Dr. Cree that name 2 trials.

CMS Open Payments shows 376 general payments to Dr. Cree from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 59% of the total. Novartis Pharma AG paid the most, $112,647. It also lists 117 research payments totaling $115,778 from 2016 to 2025, naming 2 clinical trials.

Dmand AI lists 2 awards for Dr. Cree, most recently Regional Top Doctor in 2014.

Dr. Cree graduated from UCSF School of Medicine in 1997.

Dr. Cree is in network with 7 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.